d-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
IMPORTANCE: It is unclear whether d-cycloserine (DCS), a partial N-methyl-d-aspartate agonist that enhances fear extinction, can augment the effects of exposure-based cognitive behavioral therapy (CBT) for obsessive-compulsive disorder (OCD). OBJECTIVES: To examine whether DCS augments the effects of CBT for OCD and to explore (post hoc) whether concomitant antidepressant medication moderates the effects of DCS. DESIGN, SETTING, AND PARTICIPANTS: A 12-week, double-blind randomized clinical trial with 3-month follow-up conducted at an academic medical center between September 4, 2012, and September 26, 2013. Participants included 128 adult outpatients with a primary diagnosis of OCD and a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score of 16 or higher. Concurrent antidepressant medication was permitted if the dose had been stable for at least 2 months prior to enrollment and remained unchanged during the trial. The main analysis was by intention-to-treat population. INTERVENTIONS: All participants received a previously validated Internet-based CBT protocol over 12 weeks and were randomized to receive either 50 mg of DCS or placebo, administered 1 hour before each of 5 exposure and response prevention tasks. MAIN OUTCOMES AND MEASURES: Clinician-administered Y-BOCS score at week 12 and at 3-month follow-up. Remission was defined as a score of 12 or lower on the Y-BOCS. RESULTS: In the primary intention-to-treat analyses, DCS did not augment the effects of CBT compared with placebo (mean [SD] clinician-rated Y-BOCS score, DCS: 13.86 [6.50] at week 12 and 12.35 [7.75] at 3-month follow-up; placebo: 11.77 [5.95] at week 12 and 12.37 [6.68] at 3-month follow-up) but showed a significant interaction with antidepressants (clinician-rated Y-BOCS, B = -1.08; Z = -2.79; P = .005). Post hoc analyses revealed that antidepressants significantly impaired treatment response in the DCS group but not the placebo group, at both posttreatment and follow-up (clinician-rated Y-BOCS: t62 = -3.00; P = .004; and t61 = -3.49; P < .001, respectively). In the DCS group, a significantly greater proportion of antidepressant-free patients achieved remission status at follow-up (60% [95% CI, 45%-74%]) than antidepressant-medicated patients (24% [95% CI, 9%-48%]) (P = .008). Antidepressants had no effect in the placebo group (50% [95% CI, 36%-64%] remission rate in both groups). CONCLUSIONS AND RELEVANCE: The findings suggest that antidepressants may interact with DCS to block its facilitating effect on fear extinction. Use of DCS may be a promising CBT augmentation strategy but only in antidepressant-free patients with OCD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01649895.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
The Obsessive-Compulsive Inventory: Development and validation of a short version.
Foa, E. B., Huppert, J. D., Leiberg, S., Langner, R., Kichic, R., Hajcak, G., & Salkovskis, P. M. (2002) · Psychological Assessment · doi:10.1037/1040-3590.14.4.485 · Cited by 2,959
Advantages and limitations of Internet-based interventions for common mental disorders
Andersson, G., & Titov, N. (2014) · World Psychiatry · doi:10.1002/wps.20083 · Cited by 1,160 · cited 1×
“College/university <3 y 14 (22) 12 (19)”
Self-citationFoa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048
Abramowitz, J. S., Taylor, S., & McKay, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60240-3 · Cited by 1,002
Farmer, K. C. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(99)80026-5 · Cited by 889
Svanborg, P., & Åsberg, M. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb01480.x · Cited by 693
Augmentation of Exposure Therapy With D-Cycloserine for Social Anxiety Disorder
Hofmann, S. G., Meuret, A. E., Smits, J. A. J., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., & Otto, M. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.298 · Cited by 560 · cited 1×
“College/university >3 y 25 (39) 32 (50)”
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510
Cited by
Internet-Delivered Psychological Treatments
Andersson, G. (2016) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-021815-093006 · Cited by 595
Self-citationUnusual Amino Acids in Medicinal Chemistry
Blaskovich, M. A. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00319 · Cited by 635
Andersson, G., Carlbring, P., Titov, N., & Lindefors, N. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719839381 · Cited by 324
Self-citationPittig, A., Treanor, M., LeBeau, R. T., & Craske, M. G. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.03.015 · Cited by 300
Mataix-Cols, D., Fernández de la Cruz, L., Monzani, B., Rosenfield, D., Andersson, E., Pérez-Vigil, A., Frumento, P., de Kleine, R. A., Difede, J., Dunlop, B. W., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.3955 · Cited by 288
Self-citationLenhard, F., Andersson, E., Mataix-Cols, D., Rück, C., Vigerland, S., Högström, J., Hillborg, M., Brander, G., Ljungström, M., Ljótsson, B., et al. (2017) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2016.09.515 · Cited by 146
New Directions in the Cognitive-Behavioral Treatment of OCD: Theory, Research, and Practice
Abramowitz, J. S., Blakey, S. M., Reuman, L., & Buchholz, J. L. (2018) · Behavior Therapy · doi:10.1016/j.beth.2017.09.002 · Cited by 98
Lenhard, F., Sauer, S., Andersson, E., Månsson, K. N., Mataix‐Cols, D., Rück, C., & Serlachius, E. (2018) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1576 · Cited by 84
“However, several studies of ICBT in adult OCD have reported large treatment effects, on par with effects found in face ‐ to ‐ face CBT (Andersson et al., 2011, 2012, 2015; Wootton, Dear, Johnston, Terides, & Titov, 2013).”
BackgroundSelf-citationGlutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83
“A larger randomized, double blind, placebo controlled trial was recently conducted in 128 adult OCD outpatients [134] to whom placebo or DCS was administered 1 h before 5 CBT tasks during a 12 weeks course of internet-based CBT training.”
MethodLundström, L., Flygare, O., Andersson, E., Enander, J., Bottai, M., Ivanov, V. Z., Boberg, J., Pascal, D., Mataix-Cols, D., & Rück, C. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.1967 · Cited by 78
Self-citationEnhancement of psychosocial treatment with D-cycloserine: Models, moderators, and future directions
Otto, M. W., Kredlow, M. A., Smits, J. A. J., Hofmann, S. G., Tolin, D. F., de Kleine, R. A., van Minnen, A., Evins, A. E., & Pollack, M. H. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.09.007 · Cited by 70
Rief, W., Barsky, A. J., Bingel, U., Doering, B. K., Schwarting, R., Wöhr, M., & Schweiger, U. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.11.008 · Cited by 67
Glutamatergic agents for OCD and related disorders
Pittenger, C. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0051-8 · Cited by 62
Internet-assisted cognitive behavioral therapy
Andersson, G., & Carlbring, P. (2017) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2017.08.004 · Cited by 45
Bürkner, P.-C., Bittner, N., Holling, H., & Buhlmann, U. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173660 · Cited by 41
Lenhard, F., Vigerland, S., Engberg, H., Hallberg, A., Thermaenius, H., & Serlachius, E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164311 · Cited by 37
Leveraging cognitive neuroscience for making and breaking real-world habits
Buabang, E. K., Donegan, K. R., Rafei, P., & Gillan, C. M. (2025) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2024.10.006 · Cited by 34
Mao, L., Hu, M., Luo, L., Wu, Y., Lu, Z., & Zou, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.973838 · Cited by 29
“not taking antidepressants, and DCS may be utilized as an intensive CBT treatment approach in patients with OCD who are not on antidepressants (19).”
MethodResultTolin, D. F. (2017) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2017.08.007 · Cited by 25
Innovations in the delivery of exposure and response prevention for obsessive-compulsive disorder
Patel, S. R., Comer, J., & Simpson, H. B. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2020_202 · Cited by 24
Farrell, L. J., Waters, A. M., Tiralongo, E., Mathieu, S., McKenzie, M., Garbharran, V., Ware, R. S., Zimmer‐Gembeck, M. J., McConnell, H., Lavell, C., et al. (2022) · Depression and Anxiety · doi:10.1002/da.23242 · Cited by 23
Hedman, E., Ljótsson, B., Axelsson, E., Andersson, G., Rück, C., & Andersson, E. (2017) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2016.11.007 · Cited by 20
Self-citationAndersson, E., Ljótsson, B., Hedman-Lagerlöf, M., Nygren, L., Persson, M., Rosengren, K., Gezelius, A., Andersson, L., Sundquist, T., Ivanov, V. Z., et al. (2021) · Psychological Medicine · doi:10.1017/s0033291720000781 · Cited by 10
Self-citationOlofsdotter Lauri, K., Aspvall, K., Bagøien Hustad, I., Malmqvist, K., Serlachius, E., Mataix‐Cols, D., Rück, C., Ivanov, V., & Andersson, E. (2022) · British Journal of Clinical Psychology · doi:10.1111/bjc.12369 · Cited by 9
“B Adverse events were collected by using a self- rated questionnaire (Andersson et al., 2015).”
MethodSelf-citationA precision medicine approach to pharmacological adjuncts to extinction: A call to broaden research
King, G., Baker, K. D., Bisby, M. A., Chan, D., Cowan, C. S. M., Stylianakis, A. A., Zimmermann, K. S., & Richardson, R. (2019) · Psychopharmacology · doi:10.1007/s00213-018-4999-0 · Cited by 6
Metadata
- Authors
- Andersson, E., Hedman, E., Enander, J., Radu Djurfeldt, D., Ljótsson, B., Cervenka, S., Isung, J., Svanborg, C., Mataix-Cols, D., Kaldo, V., Andersson, G., Lindefors, N., & Rück, C.
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2015-07-01
- Volume
- 72
- Issue
- 7
- Pages
- 659
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W1487315310
- Cited by
- 109
- References
- 25
- FWCI
- 21.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.